InnoCare Pharma (HKG:9969, SHA:688428) said the 80 mg once daily dose of its BTK inhibitor, Orelabrutinib, for the treatment of relapsing-remitting multiple sclerosis, was selected for phase 3 progressive multiple sclerosis studies following a demonstration of efficacy and safety profile.
The company's phase 2 results were released at the 10th annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum. These results will be presented as the on-site poster at the forum on Thursday, a Wednesday bourse filing said.
Orelabrutinib is a selective brain-penetrant BTK inhibitor that inhibits B cell, microglia, and macrophage activation in the central nervous system along with inhibiting macrophage activation.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。